Dengue fever, transmitted by Aedes mosquitoes, is becoming a significant global health threat, especially in South and Southeast Asia, where countries like India, Indonesia, and Thailand are severely affected. In India, over 232,000 cases were reported in 2024, but the actual burden is estimated to be between 2.5 to 7.5 million due to underreporting. The disease presents with symptoms that overlap with other infections, complicating early diagnosis and treatment. Currently, there is no specific antiviral treatment for dengue; care is limited to managing symptoms and monitoring for complications. The economic burden of dengue is substantial, costing India approximately $5.71 billion in 2016. The Dengue Alliance, established in 2022, is working to develop affordable treatments through collaborative research and clinical trials. Sustained investment in research and development is essential to address the treatment gap and ensure effective care for vulnerable populations, including children and pregnant women. As the need for effective treatments grows, innovative approaches and partnerships will be crucial in combating this persistent health challenge.